HC Wainwright reaffirmed their buy rating on shares of Immix Biopharma (NASDAQ:IMMX – Free Report) in a research note published on Monday morning, Benzinga reports. The brokerage currently has a $7.00 target price on the stock. HC Wainwright also issued estimates for Immix Biopharma’s Q3 2024 earnings at ($0.16) EPS, Q4 2024 earnings at ($0.17) EPS, FY2024 earnings at ($0.67) EPS, Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.52) EPS.
Immix Biopharma Trading Down 3.1 %
NASDAQ IMMX opened at $2.21 on Monday. Immix Biopharma has a 12 month low of $1.75 and a 12 month high of $7.75. The stock has a market cap of $58.37 million, a PE ratio of -2.38 and a beta of 0.17. The stock’s 50 day moving average is $2.10 and its 200 day moving average is $2.46.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.06. On average, analysts forecast that Immix Biopharma will post -0.88 EPS for the current fiscal year.
Institutional Inflows and Outflows
Immix Biopharma Company Profile
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Recommended Stories
- Five stocks we like better than Immix Biopharma
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Advance Auto Parts Eyes Long-Term Growth Despite Q2 Hurdles
- Manufacturing Stocks Investing
- Toll Brothers Stock Up on Q3 Beat: Luxury Homes Drive Growth
- Stock Dividend Cuts Happen Are You Ready?
- 4 No-Brainer Stocks to Hold This Fall for Steady Gains
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.